SOPHiA GENETICS, a cloud-native healthcare technology company, has integrated Indian precision molecular diagnostics firm Dhiti Omics Technologies on its SOPHiA DDM Platform.

The SOPHiA DDM Platform analyses complex genomic and multimodal data to deliver real-time, actionable insights to a diverse global network including hospitals, laboratories, and biopharma institutions.

Dhiti Omics will use the SOPHiA DDM Platform technology to improve its solid tumour testing capabilities.

The company specialises in molecular diagnostics and genetic testing.

By integrating SOPHiA’s platform into the Agilent SureSelect Cancer CGP application, Dhiti Omics aims to enhance its capability to deliver researchers actionable insights into mutations and biomarkers across several genes.

Dhiti Omics Technologies founder and director Sudha Rao said: “Our team at Dhiti Omics is passionate about furthering the use of precision medicine and ensuring people in India and throughout the world have access to testing for better health outcomes.

“Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximise insights from comprehensive genomic profiling data.

“This will ensure we’re delivering the fastest and most accurate diagnostics to our customer base.”

SOPHiA DDM for SureSelect CGP application combines Agilent’s genomic profiling assay kit with the SOPHiA DDM Platform.

Introduced in 2023, the SureSelect Cancer CGP application is said to provide extensive genomic profiling capabilities.

By leveraging the SOPHiA DDM AI Platform, Dhiti Omics will integrate a solution that enables rapid and precise insights based on current guidelines, focusing on relevant biomarkers.

SOPHiA GENETICS LAPAC managing director Ricardo Mendonca Filho said: “Our Platform and applications are designed to enable companies like Dhiti Omics to more easily advance precision medicine.

“By using SOPHiA DDM, Dhiti Omics can ensure speed and accuracy of solid tumour testing to best support the Indian population.”

Last month, the Nasdaq-listed SOPHiA GENETICS integrated Austria-based Kepler Uniklinikum hospital on its SOPHiA DDM Platform.

Kepler Uniklinikum will use the platform to boost its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers.